Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00694382
Other study ID # EFC6521
Secondary ID 2007-007943-29
Status Completed
Phase Phase 3
First received May 7, 2008
Last updated January 14, 2013
Start date June 2008
Est. completion date November 2010

Study information

Verified date January 2013
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The primary objective was to compare the efficacy of once daily subcutaneous injections of Semuloparin sodium (AVE5026) with placebo in the prevention of venous thromboembolism [VTE] in cancer patients at high risk for VTE and who were undergoing chemotherapy.

The secondary objectives were to evaluate the safety of Semuloparin sodium (AVE5026), to document Semuloparin sodium (AVE5026) exposures, to try identifying a metagene predictor of VTE and to assess the survival status at one year in this population.


Description:

Randomization had to take place just prior to the first study drug injection (randomization ratio 1:1).

The study period per participant was variable depending on the duration of chemotherapy. It included:

- a screening period up to 3 weeks,

- a double-blind treatment period,

- a follow-up period of 1 month.

Study end date was at the latest 7 months following the randomization of the last participant (6 months treatment and 1 month follow-up).


Recruitment information / eligibility

Status Completed
Enrollment 3212
Est. completion date November 2010
Est. primary completion date November 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

Cancer patient with metastatic or locally advanced solid tumor of lung, pancreas, stomach, colon/rectum, bladder or ovary initiating a (new) course of chemotherapy with a minimum intent of 3 months therapy

Exclusion Criteria:

- Required systematic venous thromboprophylaxis or curative treatment with anti-coagulant or thrombolytic;

- High risk of bleeding;

- Severe renal impairment (estimated creatinine clearance <30 mL/min);

- ECOG (Eastern Cooperative Oncology Group) performance status 3 & 4;

- Major surgery within 4 weeks before randomization;

- Known hypersensitivity to unfractionated heparin [UFH] or low molecular weight heparin [LMWH].

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
Semuloparin sodium
0.4 mL solution in ready-to-use 0.5 ml pre-filled syringe Subcutaneous injection
Placebo (for semuloparin)
0.4 mL solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component Subcutaneous injection

Locations

Country Name City State
Argentina Investigational Site Number 032006 Buenos Aires
Argentina Investigational Site Number 032003 Capital Federal
Argentina Investigational Site Number 032004 Rosario
Argentina Investigational Site Number 032005 San Miguel De Tucuman
Argentina Investigational Site Number 032007 Tucuman
Australia Investigational Site Number 036004 Adelaide
Australia Investigational Site Number 036002 Bedford Park
Australia Investigational Site Number 036001 Box Hill
Australia Investigational Site Number 036009 Lismore
Australia Investigational Site Number 036007 Perth
Australia Investigational Site Number 036006 Ringwood East
Australia Investigational Site Number 036008 Westmead
Australia Investigational Site Number 036003 Woodville
Australia Investigational Site Number 036005 Woolloongabba
Austria Investigational Site Number 040002 Graz
Austria Investigational Site Number 040003 Wien
Austria Investigational Site Number 040004 Wien
Belarus Investigational Site Number 112002 Gomel
Belarus Investigational Site Number 112001 Minsk
Belarus Investigational Site Number 112003 Minsk
Belarus Investigational Site Number 112004 Vitebsk
Belgium Investigational Site Number 056008 Bonheiden
Belgium Investigational Site Number 056011 Brussels
Belgium Investigational Site Number 056005 Gent
Belgium Investigational Site Number 056010 Haine-Saint-Paul
Belgium Investigational Site Number 056006 Kortrijk
Belgium Investigational Site Number 056009 Liège
Belgium Investigational Site Number 056004 Merksem
Belgium Investigational Site Number 056003 Oostende
Belgium Investigational Site Number 056012 Ottignies
Belgium Investigational Site Number 056002 Sint Niklaas
Brazil Investigational Site Number 076002 Belo Horizonte
Brazil Investigational Site Number 076015 Curitiba
Brazil Investigational Site Number 076022 Curitiba
Brazil Investigational Site Number 076012 Florianopolis
Brazil Investigational Site Number 076001 Fortaleza
Brazil Investigational Site Number 076007 Goiania
Brazil Investigational Site Number 076009 Goiania
Brazil Investigational Site Number 076016 Goiania
Brazil Investigational Site Number 076024 Ijui
Brazil Investigational Site Number 076003 Joinville
Brazil Investigational Site Number 076010 Londrina
Brazil Investigational Site Number 076026 Passo Fundo
Brazil Investigational Site Number 076027 Passo Fundo
Brazil Investigational Site Number 076020 Porto Alegre
Brazil Investigational Site Number 076023 Porto Alegre
Brazil Investigational Site Number 076014 Salvador
Brazil Investigational Site Number 076018 Salvador
Brazil Investigational Site Number 076011 Santo Andre
Brazil Investigational Site Number 076006 Sao Jose Dos Campos
Brazil Investigational Site Number 076008 Sao Paulo
Brazil Investigational Site Number 076017 Sao Paulo
Brazil Investigational Site Number 076004 Taguatinga
Bulgaria Investigational Site Number 100001 Rousse
Bulgaria Investigational Site Number 100003 Varna
Canada Investigational Site Number 124008 Greenfield Park
Canada Investigational Site Number 124007 Kelowna
Canada Investigational Site Number 124010 Moncton
Canada Investigational Site Number 124003 Montreal
Canada Investigational Site Number 124002 Ottawa
Canada Investigational Site Number 124009 Owen Sound
Canada Investigational Site Number 124006 Rimouski
Canada Investigational Site Number 124013 Saint John
Canada Investigational Site Number 124001 Sherbrooke
Canada Investigational Site Number 124012 Victoria
Canada Investigational Site Number 124011 Weston
Chile Investigational Site Number 152002 Temuco
China Investigational Site Number 156008 Beijing
China Investigational Site Number 156014 Beijing
China Investigational Site Number 156022 Beijing
China Investigational Site Number 156031 Changchun
China Investigational Site Number 156021 Chengdu
China Investigational Site Number 156019 Chongqing
China Investigational Site Number 156003 Dalian
China Investigational Site Number 156025 Guangzhou
China Investigational Site Number 156026 Hangzhou
China Investigational Site Number 156030 Nanning
China Investigational Site Number 156029 Qingdao
China Investigational Site Number 156011 Shanghai
China Investigational Site Number 156020 Shanghai
China Investigational Site Number 156024 Shanghai
China Investigational Site Number 156028 Shanghai
China Investigational Site Number 156013 Shantou
China Investigational Site Number 156012 Suzhou
China Investigational Site Number 156004 Xi'An
China Investigational Site Number 156009 Xi'An
China Investigational Site Number 156027 Yinchuan
Colombia Investigational Site Number 170010 Bogota
Colombia Investigational Site Number 170005 Manizales
Colombia Investigational Site Number 170002 Medellin
Colombia Investigational Site Number 170006 Medellin
Colombia Investigational Site Number 170007 Medellín
Colombia Investigational Site Number 170008 Monteria
Colombia Investigational Site Number 170004 Pereira
Croatia Investigational Site Number 191006 Pula
Croatia Investigational Site Number 191005 Rijeka
Croatia Investigational Site Number 191007 Varazdin
Croatia Investigational Site Number 191003 Zadar
Croatia Investigational Site Number 191001 Zagreb
Croatia Investigational Site Number 191004 Zagreb
Croatia Investigational Site Number 191008 Zagreb
Czech Republic Investigational Site Number 203004 Hradec Kralove
Czech Republic Investigational Site Number 203008 Kolin
Czech Republic Investigational Site Number 203007 Nova Ves Pod Plesi
Czech Republic Investigational Site Number 203003 Praha 5
Denmark Investigational Site Number 208001 Herlev
Estonia Investigational Site Number 233001 Tallinn
Finland Investigational Site Number 246001 Turku
France Investigational Site Number 250002 Antibes
France Investigational Site Number 250010 Colmar
France Investigational Site Number 250020 Gap
France Investigational Site Number 250005 Lille Cedex
France Investigational Site Number 250012 Lille Cedex
France Investigational Site Number 250025 Lille Cedex
France Investigational Site Number 250003 Lyon
France Investigational Site Number 250001 Marseille
France Investigational Site Number 250024 Montpellier Cedex
France Investigational Site Number 250006 Paris Cedex 10
France Investigational Site Number 250027 Paris Cedex 10
France Investigational Site Number 250004 Paris Cedex 14
France Investigational Site Number 250021 Reims
France Investigational Site Number 250019 Rouen
France Investigational Site Number 250017 Saint Gregoire
France Investigational Site Number 250014 Vandoeuvre Les Nancy
Germany Investigational Site Number 276012 Augsburg
Germany Investigational Site Number 276002 Berlin
Germany Investigational Site Number 276016 Berlin
Germany Investigational Site Number 276025 Berlin
Germany Investigational Site Number 276029 Berlin
Germany Investigational Site Number 276004 Bochum
Germany Investigational Site Number 276009 Dresden
Germany Investigational Site Number 276014 Dresden
Germany Investigational Site Number 276030 Essen
Germany Investigational Site Number 276005 Frankfurt Am Main
Germany Investigational Site Number 276032 Gauting
Germany Investigational Site Number 276034 Halle
Germany Investigational Site Number 276038 Halle/Saale
Germany Investigational Site Number 276037 Hamburg
Germany Investigational Site Number 276007 Hannover
Germany Investigational Site Number 276006 Köln
Germany Investigational Site Number 276020 Leer
Germany Investigational Site Number 276010 Leipzig
Germany Investigational Site Number 276017 Magdeburg
Germany Investigational Site Number 276011 Mannheim
Germany Investigational Site Number 276003 Minden
Germany Investigational Site Number 276015 München
Germany Investigational Site Number 276019 München
Germany Investigational Site Number 276021 München
Germany Investigational Site Number 276013 Neumünster
Germany Investigational Site Number 276022 Oldenburg
Germany Investigational Site Number 276035 Paderborn
Germany Investigational Site Number 276031 Passau
Germany Investigational Site Number 276023 Rosenheim
Germany Investigational Site Number 276008 Singen
Germany Investigational Site Number 276024 Westerstede
Greece Investigational Site Number 300004 Athens
Greece Investigational Site Number 300003 Heraklion
Greece Investigational Site Number 300002 Thessaloniki
Hong Kong Investigational Site Number 344001 Hong Kong
Hungary Investigational Site Number 348004 Budapest
Hungary Investigational Site Number 348005 Budapest
Hungary Investigational Site Number 348006 Budapest
Hungary Investigational Site Number 348009 Budapest
Hungary Investigational Site Number 348010 Farkasgyepu
Hungary Investigational Site Number 348001 Gyula
Hungary Investigational Site Number 348012 Mátraháza
Hungary Investigational Site Number 348003 Sopron
Hungary Investigational Site Number 348008 Szikszó
Hungary Investigational Site Number 348011 Szolnok
Hungary Investigational Site Number 348007 Zalaegerszeg
India Investigational Site Number 356006 Bangalore
India Investigational Site Number 356008 Bangalore
India Investigational Site Number 356009 Bhopal
India Investigational Site Number 356018 Chennai
India Investigational Site Number 356020 Chennai
India Investigational Site Number 356019 Coimbatore
India Investigational Site Number 356015 Hyderabad
India Investigational Site Number 356025 Hyderabad
India Investigational Site Number 356011 Jaipur
India Investigational Site Number 356014 Kochi
India Investigational Site Number 356003 Kolkata
India Investigational Site Number 356013 Kolkata
India Investigational Site Number 356017 Kolkata
India Investigational Site Number 356005 Madurai
India Investigational Site Number 356016 Miraj
India Investigational Site Number 356001 Mumbai
India Investigational Site Number 356023 Nagpur
India Investigational Site Number 356002 New Delhi
India Investigational Site Number 356004 Pune
India Investigational Site Number 356024 Pune
India Investigational Site Number 356012 Vishakhapatnam
Indonesia Investigational Site Number 360002 Bandung
Indonesia Investigational Site Number 360001 Denpasar
Indonesia Investigational Site Number 360004 Medan
Ireland Investigational Site Number 372002 Dublin
Ireland Investigational Site Number 372003 Dublin
Ireland Investigational Site Number 372004 Dublin 7
Israel Investigational Site Number 376003 Jerusalem
Israel Investigational Site Number 376004 Kfar Saba
Israel Investigational Site Number 376001 Nahariya
Israel Investigational Site Number 376006 Petah-Tikva
Israel Investigational Site Number 376007 Tzrifin
Italy Investigational Site Number 380005 Castellanza
Italy Investigational Site Number 380014 Cattolica
Italy Investigational Site Number 380007 Cesena
Italy Investigational Site Number 380015 Cremona
Italy Investigational Site Number 380009 Faenza
Italy Investigational Site Number 380012 Lecce
Italy Investigational Site Number 380006 Lugo
Italy Investigational Site Number 380001 Meldola
Italy Investigational Site Number 380011 Parma
Italy Investigational Site Number 380020 Perugia
Italy Investigational Site Number 380013 Ravenna
Italy Investigational Site Number 380016 Rimini
Italy Investigational Site Number 380004 Sondrio
Italy Investigational Site Number 380010 Sora
Italy Investigational Site Number 380008 Taormina
Italy Investigational Site Number 380019 Terni
Italy Investigational Site Number 380003 Treviglio
Italy Investigational Site Number 380017 Udine
Korea, Republic of Investigational Site Number 410008 Daegu
Korea, Republic of Investigational Site Number 410001 Seoul
Korea, Republic of Investigational Site Number 410002 Seoul
Korea, Republic of Investigational Site Number 410003 Seoul
Korea, Republic of Investigational Site Number 410005 Seoul
Korea, Republic of Investigational Site Number 410006 Seoul
Korea, Republic of Investigational Site Number 410007 Seoul
Korea, Republic of Investigational Site Number 410009 Seoul
Korea, Republic of Investigational Site Number 410004 Suwon
Latvia Investigational Site Number 428002 Liepaja
Latvia Investigational Site Number 428001 Riga
Latvia Investigational Site Number 428003 Riga
Lithuania Investigational Site Number 440001 Kaunas
Lithuania Investigational Site Number 440002 Vilnius
Malaysia Investigational Site Number 458001 Kota Kinabalu
Malaysia Investigational Site Number 458003 Kuala Lumpur
Malaysia Investigational Site Number 458004 Penang
Malaysia Investigational Site Number 458005 Penang
Mexico Investigational Site Number 484002 Acapulco
Mexico Investigational Site Number 484006 Aguascalientes
Mexico Investigational Site Number 484007 Durango
Mexico Investigational Site Number 484008 Mérida
Mexico Investigational Site Number 484012 Puebla
Mexico Investigational Site Number 484003 Toluca
Mexico Investigational Site Number 484010 Xalapa
Netherlands Investigational Site Number 528006 Den Haag
Netherlands Investigational Site Number 528004 Groningen
Netherlands Investigational Site Number 528005 Helmond
Netherlands Investigational Site Number 528001 Hoofddorp
Netherlands Investigational Site Number 528003 Rotterdam
Norway Investigational Site Number 578001 Oslo
Peru Investigational Site Number 604012 Arequipa
Peru Investigational Site Number 604004 Callao
Peru Investigational Site Number 604011 Callao
Peru Investigational Site Number 604001 Cercado
Peru Investigational Site Number 604002 Chiclayo
Peru Investigational Site Number 604003 Lima
Peru Investigational Site Number 604005 Lima
Peru Investigational Site Number 604006 Lima
Peru Investigational Site Number 604007 Lima
Peru Investigational Site Number 604008 Lima
Peru Investigational Site Number 604009 Lima
Peru Investigational Site Number 604010 Lima
Poland Investigational Site Number 616009 Bialystok
Poland Investigational Site Number 616008 Bielsko-Biala
Poland Investigational Site Number 616006 Gliwice
Poland Investigational Site Number 616004 Krakow
Poland Investigational Site Number 616003 Lubin
Poland Investigational Site Number 616019 Olsztyn
Poland Investigational Site Number 616021 Otwock
Poland Investigational Site Number 616010 Poznan
Poland Investigational Site Number 616001 Prabuty
Poland Investigational Site Number 616014 Rybnik
Poland Investigational Site Number 616005 Rzeszow
Poland Investigational Site Number 616013 Torun
Poland Investigational Site Number 616002 Warszawa
Poland Investigational Site Number 616018 Warszawa
Poland Investigational Site Number 616015 Wroclaw
Portugal Investigational Site Number 620003 Aveiro
Portugal Investigational Site Number 620009 Guimarães
Portugal Investigational Site Number 620004 Lisboa
Portugal Investigational Site Number 620008 Matosinhos
Portugal Investigational Site Number 620007 Porto
Portugal Investigational Site Number 620002 Setúbal
Romania Investigational Site Number 642004 Brasov
Romania Investigational Site Number 642002 Bucuresti
Romania Investigational Site Number 642001 Cluj Napoca
Romania Investigational Site Number 642006 Cluj-Napoca
Romania Investigational Site Number 642010 Iasi
Romania Investigational Site Number 642003 Suceava
Romania Investigational Site Number 642008 Timisoara
Russian Federation Investigational Site Number 643024 Berdsk
Russian Federation Investigational Site Number 643006 Chelyabinsk
Russian Federation Investigational Site Number 643001 Kazan
Russian Federation Investigational Site Number 643004 Krasnoyarsk
Russian Federation Investigational Site Number 643010 Obninsk
Russian Federation Investigational Site Number 643005 Omsk
Russian Federation Investigational Site Number 643022 Pyatigorsk
Russian Federation Investigational Site Number 643023 Rostov-On-Don
Russian Federation Investigational Site Number 643020 Saratov
Russian Federation Investigational Site Number 643019 Smolensk
Russian Federation Investigational Site Number 643021 Sochi
Russian Federation Investigational Site Number 643011 St-Petersburg
Russian Federation Investigational Site Number 643014 St-Petersburg
Russian Federation Investigational Site Number 643015 St-Petersburg
Russian Federation Investigational Site Number 643009 St.Petersburg
Russian Federation Investigational Site Number 643008 Tomsk
Russian Federation Investigational Site Number 643016 Tula
Russian Federation Investigational Site Number 643018 Tyumen
Russian Federation Investigational Site Number 643012 Ufa
Russian Federation Investigational Site Number 643007 Vladivostok
Russian Federation Investigational Site Number 643017 Voronezh
Russian Federation Investigational Site Number 643003 Yaroslavl
Serbia Investigational Site Number 688002 Belgrade
Serbia Investigational Site Number 688004 Belgrade
Serbia Investigational Site Number 688007 Kragujevac
Serbia Investigational Site Number 688005 Nis
Slovakia Investigational Site Number 703003 Trnava
Slovenia Investigational Site Number 705003 Golnik
Slovenia Investigational Site Number 705002 Maribor
South Africa Investigational Site Number 710002 Durban
South Africa Investigational Site Number 710003 Durban
Spain Investigational Site Number 724008 Barakaldo
Spain Investigational Site Number 724010 Barakaldo
Spain Investigational Site Number 724004 Barcelona
Spain Investigational Site Number 724006 Islas Baleares
Spain Investigational Site Number 724011 Lérida
Spain Investigational Site Number 724001 Madrid
Spain Investigational Site Number 724007 Madrid
Spain Investigational Site Number 724012 Madrid
Spain Investigational Site Number 724013 Madrid
Spain Investigational Site Number 724005 Orense
Spain Investigational Site Number 724003 Puerto De Sagunto
Spain Investigational Site Number 724002 Valencia
Sweden Investigational Site Number 752003 Göteborg
Sweden Investigational Site Number 752005 Mora
Sweden Investigational Site Number 752002 Uppsala
Sweden Investigational Site Number 752001 Växjö
Switzerland Investigational Site Number 756006 Aarau
Switzerland Investigational Site Number 756004 Winterthur
Taiwan Investigational Site Number 158004 Changhua
Ukraine Investigational Site Number 804008 Cherkasy
Ukraine Investigational Site Number 804009 Chernivtsi
Ukraine Investigational Site Number 804002 Dnipropetrovsk
Ukraine Investigational Site Number 804006 Donetsk
Ukraine Investigational Site Number 804005 Krivoy Rog
Ukraine Investigational Site Number 804001 Lutsk
Ukraine Investigational Site Number 804010 Lviv
Ukraine Investigational Site Number 804011 Sumy
Ukraine Investigational Site Number 804004 Ternopil
United Kingdom Investigational Site Number 826016 Bangor
United Kingdom Investigational Site Number 826010 Brighton
United Kingdom Investigational Site Number 826015 Coventry
United Kingdom Investigational Site Number 826013 Dundee
United Kingdom Investigational Site Number 826007 Hull
United Kingdom Investigational Site Number 826002 Lincoln
United Kingdom Investigational Site Number 826017 Lincoln
United Kingdom Investigational Site Number 826005 Manchester
United Kingdom Investigational Site Number 826004 Norwich
United Kingdom Investigational Site Number 826009 Peterborough
United Kingdom Investigational Site Number 826011 Portsmouth
United Kingdom Investigational Site Number 826001 Shrewsbury
United Kingdom Investigational Site Number 826014 Wirral
United States Investigational Site Number 840067 Beaumont Texas
United States Investigational Site Number 840042 Bethesda Maryland
United States Investigational Site Number 840006 Birmingham Alabama
United States Investigational Site Number 840046 Bismarck North Dakota
United States Investigational Site Number 840007 Casa Grande Arizona
United States Investigational Site Number 840074 Clearwater Florida
United States Investigational Site Number 840020 Durham North Carolina
United States Investigational Site Number 840021 Durham North Carolina
United States Investigational Site Number 840075 East Providence Rhode Island
United States Investigational Site Number 840066 Easton Maryland
United States Investigational Site Number 840004 El Paso Texas
United States Investigational Site Number 840050 Fountain Valley California
United States Investigational Site Number 840072 Fullerton California
United States Investigational Site Number 840033 Goshen Indiana
United States Investigational Site Number 840026 High Point North Carolina
United States Investigational Site Number 840034 Houston Texas
United States Investigational Site Number 840037 Indian Wells California
United States Investigational Site Number 840010 Indianapolis Indiana
United States Investigational Site Number 840019 Jacksonville Florida
United States Investigational Site Number 840063 Kennewick Washington
United States Investigational Site Number 840069 La Verne California
United States Investigational Site Number 840009 Long Beach California
United States Investigational Site Number 840014 Louisville Kentucky
United States Investigational Site Number 840047 Metairie Louisiana
United States Investigational Site Number 840003 Middletown Ohio
United States Investigational Site Number 840048 Mount Sterling Kentucky
United States Investigational Site Number 840005 Norwich Connecticut
United States Investigational Site Number 840001 Oceanside California
United States Investigational Site Number 840016 Park Ridge Illinois
United States Investigational Site Number 840028 Quincy Illinois
United States Investigational Site Number 840011 Rancho Mirage California
United States Investigational Site Number 840024 Rochester New York
United States Investigational Site Number 840051 Rockledge Florida
United States Investigational Site Number 840070 Roswell Georgia
United States Investigational Site Number 840032 Ruston Louisiana
United States Investigational Site Number 840073 Sarasota Florida
United States Investigational Site Number 840008 Skokie Illinois
United States Investigational Site Number 840035 Sugar Land Texas
United States Investigational Site Number 840022 Sylvania Ohio
United States Investigational Site Number 840031 Syracuse New York
United States Investigational Site Number 840018 Tacoma Washington
United States Investigational Site Number 840064 Torrington Connecticut
United States Investigational Site Number 840060 Tucson Arizona
United States Investigational Site Number 840059 Tupelo Mississippi
United States Investigational Site Number 840025 Washington District of Columbia
United States Investigational Site Number 840052 Washington District of Columbia
United States Investigational Site Number 840029 West Covina California
United States Investigational Site Number 840038 Woodbridge Connecticut

Sponsors (1)

Lead Sponsor Collaborator
Sanofi

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Austria,  Belarus,  Belgium,  Brazil,  Bulgaria,  Canada,  Chile,  China,  Colombia,  Croatia,  Czech Republic,  Denmark,  Estonia,  Finland,  France,  Germany,  Greece,  Hong Kong,  Hungary,  India,  Indonesia,  Ireland,  Israel,  Italy,  Korea, Republic of,  Latvia,  Lithuania,  Malaysia,  Mexico,  Netherlands,  Norway,  Peru,  Poland,  Portugal,  Romania,  Russian Federation,  Serbia,  Slovakia,  Slovenia,  South Africa,  Spain,  Sweden,  Switzerland,  Taiwan,  Ukraine,  United Kingdom, 

References & Publications (1)

Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012 Feb 16;366(7):601-9 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Platelets Count: Percentage of Participants With Potentially Clinically Significant Abnormalities [PCSA] PCSA are abnormal values considered medically important by the Sponsor according to predefined criteria based on literature review.
Thresholds for platelet counts were defined as follows:
Platelets count <50 Giga/L;
Platelets count =50 and <100 Giga/L;
From first study drug injection up to 3 days after last study drug injection Yes
Other Liver Function: Percentage of Participants With Potentially Clinically Significant Abnormalities [PCSA] Thresholds were defined as follows:
Alanine Aminotransferase [ALAT] >3 Upper Normal Limit [ULN];
Total Bilirubin [TB] >2 ULN;
ALAT >3 ULN and TB >2 ULN;
Cases with ALAT >3 ULN and TB >2 ULN (not necessarily concomitant) were evaluated by blinded independent adjudicator to determine if they met Hy's law criteria.
From first study drug injection up to 3 days after last study drug injection Yes
Primary Percentage of Participants Who Experienced Venous Thromboembolism Event [VTE] or VTE-related Death VTE included any symptomatic Deep Vein Thrombosis [DVT] of lower or upper limbs and any non-fatal Pulmonary Embolism [PE] as confirmed by a Central Independent Adjudication Committee [CIAC] after review of compression ultrasound or venography for DVT, ventilation/perfusion lung scan, pulmonary angiogram or spiral computer tomography lung scan for PE.
VTE-related death included fatal PE and unexplained deaths without confirmatory autopsy. Any sudden death could be classified as fatal PE by the CIAC unless diagnostic test results strongly indicated an alternative diagnosis".
From randomization up to 3 days after last study drug injection No
Primary Time-to-first Occurrence of VTE or VTE-related Death (Cumulative Incidence Function) Participants alive and not having experienced VTE were right censored at last study drug injection plus 3 days. In order to correct for competing risks (Deaths other than VTE-related death), a model of cause-specific hazards was used to estimate the Cumulative incidence Function with Prentice non-parametric estimator. From randomization up to 3 days after last study drug injection No
Secondary Percentage of Participants who required the initiation of curative anticoagulant or thrombolytic treatment after VTE assessment Initiation of curative anticoagulant or thrombolytic treatment after VTE assessment was defined from investigator's answer to the question "was the subject treated for VTE?" asked after diagnostic tests for suspected VTE and after lung imaging test for tumor evaluation. From randomization up to 3 days after last study drug injection No
Secondary Percentage of Participants Who Experienced Clinically Relevant Bleedings Clinically Relevant Bleedings included overt bleedings classified by the CIAC as:
"major" (fatal, in a critical area/organ, causing a drop in hemoglobin =2 g/dL or requiring transfusion =2 units of blood)
"clinically relevant non-major" (requiring medical intervention and not meeting criteria for major bleeding).
From first study drug injection up to 3 days after last study drug injection Yes
Secondary Overall survival [OS] Survival status was collected for all participants either one year after randomization, or at the study end date, (ie, 7 months following randomization of the last patient), whichever came first.
OS was defined as the time from date of randomization to date of death due to any cause. Participants alive were censored at last date of contact that they were known to be alive.
From randomization up to 1 year after randomization or 7 months following randomization of the last participant, whichever came first No
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients